½ðºÌÓéÀÖ³Ç

In osteoporosis research and clinical practice, the value of real-world evidence (RWE) is increasingly acknowledged; but much of its potential remains untapped. By analyzing real-world treatment patterns, RWE provides deeper insights into the effectiveness of osteoporosis treatments. Unlike clinical trials, which operate under controlled conditions, RWE captures the realities of routine clinical practice.  

Worldwide, osteoporosis is estimated to cause fractures in a staggering one in three women over the age of 50, and in women over 45 years of age, osteoporosis accounts for more days in hospital than many other diseases, including diabetes, myocardial infarction and breast cancer.

With 71% of patients who sustain fractures related to osteoporosis remaining undiagnosed and untreated, data around treatment journeys is essential to help close the gap. A comprehensive picture of how patients experience care, manage their condition and navigate healthcare systems is lacking.

Highlighting the impact of RWE at WCO-IOF-ESCEO

At the 25th WCO-IOF-ESCEO?Congress in Rome, Italy, ½ðºÌÓéÀÖ³Ç, its partner, Amgen and investigators from supported investigator-initiated studies, are presenting eight abstracts, further building the body of RWE that can be used to elevate care for those at high risk of fracture.  

These data will allow us to better characterize patients at high fracture risk and get a clearer picture of their treatment journeys. These insights are guiding how we support clinicians to prioritize early, targeted interventions for patients most at risk of fracture.  

At ½ðºÌÓéÀÖ³Ç, it is our mission that everyone with osteoporosis at very high fracture risk (VHFR) receives the appropriate investigation and intervention that they need, with the aim to create a world free of fragility fractures.

We are fully embracing the opportunity that RWE brings, generating data that deepens understanding of VHFR care and informs better treatment decisions. By working closely with healthcare professionals to leverage real-world insights, we can ensure that fewer patients at very high fracture risk fall through the cracks.